Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings

We recently published 10 Resilient Stocks Defying Market Sentiment. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of Monday’s biggest gainers.

Recursion Pharmaceuticals grew its share prices for a fourth straight day on Monday, adding 9.59 percent to close at $6.40 apiece as investors repositioned portfolios ahead of its second quarter earnings results.

Based on its historical reporting dates, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) will announce the results of its performance in the first week of August 2025.

Investor excitement was further supported by a social media post by the company’s senior director, Peter Ray, about an ongoing drug candidate called REC-3565, which aims to treat relapsed or refractory B-cell lymphomas.

Now on Phase 1 trial, REC-3565 is being developed using Recursion Pharmaceuticals, Inc.’s (NASDAQ:RXRX) advanced AI platform, which is said would not conceive through traditional human design methods.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the few companies that earned the backing of technology giant Nvidia Corp., one of the key drivers of the Artificial Intelligence sector.

While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.